NEWS

Company News

CPHI Worldwide 2024

2024-09-26

2024

09-26

Taienkang will participate in CPHI – JAPAN 2024

Sichuan Taienkang Pharmaceutical Co., Ltd. will be participating as an exhibitor in the CPHI – JAPAN 2024 at Tokyo Big Sight, Tokyo, Japan.

2024-03-22

2024

03-22

CKBA, an innovative drug of Taienkang, launched the Phase II clinical trials.

On Nov. 17th, 2023, the press conference on the Phase II Clinical Trial Protocol of Innovative Drug and the China Diagnosis and Treatment Consensus Seminar for the Treatment of Vitiligo Disease were held in Shanghai. At the meeting, Taienkang officiallly announced the launch of its CKBA vitiligo drug phase II clinical trial. The day before this day, a Taienkang's subsidiary company, BCY pharm, just completed the first examinee (the patient) enrollment for the Phase II clinical trial for the Class I innovative drug-CKBA (Saccinic Acid) ointment for the treatment of vitiligo.

2023-11-21

2023

11-21

Sichuan Taienkang Pharmaceutical Co., Ltd attended the CPHI Worldwide 2023.

CPHI Worldwide 2023 was hold in Barcelona from Oct.24th to 26th . CPHI has held over 30 sessions and is the world's largest pharmaceutical industry professional exhibition, covering the entire supply chain of the pharmaceutical industry. Sichuan Taienkang Pharmaceutical Co., Ltd. attended this grand event as an exhibitor for the first time and advertised the products for APIs & intermediates, bio-generic drugs and FDFs. During the three-day exhibition, the company's products attracted many customers from all over the world, and the booth was bustling with visitors!  In the future, Taienkang will take participating in such exhibitions as an opportunity to continuously strengthen communication and cooperation with customers, continuously improve product and service levels, actively expand overseas business, and strive to be a leading international pharmaceutical company.

2023-10-27

2023

10-27

2023

Establish strategic partnership with Jiangsu BCY pharm as Taienkang’s 3rd R&D center.

2023-11-02

2023

11-02

2022

Stock-list on the GEM of Shenzhen Stock Exchange with the stock code 301263.

2023-11-02

2023

11-02

2020

Establish Sichuan Taienkang Pharmaceutical Co., Ltd.

2023-11-02

2023

11-02

Oct. 2015

Establish the R&D company Shandong Hubble Kisen Biological Technology Co., Ltd.

2023-11-02

2023

11-02

Feb. 2015

Acquire Anhui Taienkang Pharmaceutical Co., Ltd.

2023-11-02

2023

11-02

2011~2014

Complete the company’s listing reorganization and shareholding system reformation. In 2014, stock-list on the Chinese “New Third Board”.

2023-11-02

2023

11-02

< 12 > 跳转到 页

Scan QR code for mobile view

TEL.

+86-826-5999982

E-mail

sales@taienkangpharma.com

ADD.

Manufacturing Site Address: 
No. 22, Jiankang Road, 
Economic Development Zone, 
Yuechi County 638300, 
Sichuan Province, 
China.

Copyright© 2023 Sichuan Taienkang Pharmaceutical Co., Ltd.  | SEO Tags |  License |  www.300.cn